Members of the epidermal growth factor receptor tyrosine kinase
(RTK) family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4)
are key targets for inhibition in cancer therapy. Critical for
activation is the formation of a dimer in the cytoplasmic domain
that induces autophosphorylation on specific tyrosine residues. A
cytoplasmic protein, called MIG6, interacts with the cytoplasmic
domains of RTKs and inhibits their kinase domain. Based on your
knowledge of RTK signaling, what effect would you expect MIG6
overexpression in cancer cells to have...